Zhejiang Anglikang Pharmaceutical Co Ltd Class A Market Cap ($749.79 Million)
Market Cap & Net Worth: Zhejiang Anglikang Pharmaceutical Co Ltd Class A (002940)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A market cap. Zhejiang Anglikang Pharmaceutical Co Ltd Class A (SHE:002940) has a market capitalization of $749.79 Million (CN¥5.12 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #9911 globally and #2545 in its home market, demonstrating a 10.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Anglikang Pharmaceutical Co Ltd Class A's stock price CN¥25.40 by its total outstanding shares 201728186 (201.73 Million). Also see Zhejiang Anglikang Pharmaceutical Co Ltd (002940) cash conversion ratio for how efficiently the company converts equity into cash flow.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Market Cap History (2018–2026)
Zhejiang Anglikang Pharmaceutical Co Ltd Class A market cap history from 2018 to 2026. Data shows growth from $458.43 Million to $749.79 Million (7.29% CAGR). Check Zhejiang Anglikang Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Zhejiang Anglikang Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Anglikang Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 002940 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.69x
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap is 0.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.89x
Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap is 7.89 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $458.43 Million | $1.26 Billion | $108.70 Million | 0.37x | 4.22x |
| 2019 | $392.01 Million | $1.40 Billion | $112.27 Million | 0.28x | 3.49x |
| 2020 | $551.95 Million | $1.29 Billion | $163.72 Million | 0.43x | 3.37x |
| 2021 | $491.71 Million | $1.38 Billion | $119.84 Million | 0.36x | 4.10x |
| 2022 | $535.10 Million | $1.57 Billion | $127.30 Million | 0.34x | 4.20x |
| 2023 | $632.19 Million | $1.62 Billion | $138.37 Million | 0.39x | 4.57x |
| 2024 | $389.06 Million | $1.51 Billion | $80.33 Million | 0.26x | 4.84x |
| 2025 | $989.48 Million | $1.42 Billion | $125.44 Million | 0.69x | 7.89x |
Competitor Companies of 002940 by Market Capitalization
Companies near Zhejiang Anglikang Pharmaceutical Co Ltd Class A in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Zhejiang Anglikang Pharmaceutical Co Ltd for a full breakdown of the balance sheet.
Key companies related to Zhejiang Anglikang Pharmaceutical Co Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Zhejiang Anglikang Pharmaceutical Co Ltd Class A (2018–2026)
Market capitalization of Zhejiang Anglikang Pharmaceutical Co Ltd Class A from 2018 to today. Between 2018 and today, Zhejiang Anglikang Pharmaceutical Co Ltd Class A's market cap moved from $458.43 Million to $ 749.79 Million, with a yearly change of 7.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥749.79 Million | -24.22% |
| 2025 | CN¥989.48 Million | +154.32% |
| 2024 | CN¥389.06 Million | -38.46% |
| 2023 | CN¥632.19 Million | +18.14% |
| 2022 | CN¥535.10 Million | +8.82% |
| 2021 | CN¥491.71 Million | -10.91% |
| 2020 | CN¥551.95 Million | +40.80% |
| 2019 | CN¥392.01 Million | -14.49% |
| 2018 | CN¥458.43 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Zhejiang Anglikang Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $749.79 Million USD |
| MoneyControl | $749.79 Million USD |
| MarketWatch | $749.79 Million USD |
| marketcap.company | $749.79 Million USD |
| Reuters | $749.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Anglikang Pharmaceutical Co Ltd Class A
Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such … Read more